Clinical trials: Osteogenesis Imperfecta
Rotator Cuff Tendinitis, Syndrome Rotator Cuff
Performance and Safety Evaluation of MD-Shoulder Collagen Medical Device in the Treatment of Rotator Cuff Syndrome
Rotator Cuff Syndrome is a commonly encountered musculoskeletal disorder in clinical practice, with an incidence ranging from 0.3% to 5.5%, and an annual prevalence of 0.5% to 7.4%.
- Conditions
- Rotator Cuff Tendinitis, Syndrome Rotator Cuff, Tendinopathy, Tendinoses, Rotator Cuff
- Trial name
- ROPIRAMED (NCT05489484)
- Testing
- MD-Shoulder Collagen Medical Device
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Guna S.p.a
Osteogenesis Imperfecta
Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta
This is a randomized, open label intra-patient dose escalation study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of BPS804 in adults with osteogenesis imperfecta (OI).
- Trial name
- NCT01417091
- Testing
- BPS804
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 10 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteogenesis Imperfecta
Osteogenesis Imperfecta Blood Pressure Study
Osteogenesis Imperfecta (OI) is a genetic disorder caused by mutations to the alpha-1 or alpha-2 chain of type I collagen. Clinically, the disorder is characterized by bones that fracture easily, often from little or no apparent…
- Trial name
- NCT04169568
- Testing
- Manual cuff blood pressure
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Nemours Children's Clinic
Osteogenesis Imperfecta
Boost Brittle Bones Before Birth
An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of…
- Trial name
- BOOSTB4 (NCT03706482)
- Testing
- BOOST cells
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Karolinska Institutet
Osteogenesis Imperfecta
Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta
The primary objective of the study is to evaluate the effect of setrusumab on reduction in fracture rate, including morphometric vertebral fractures.
- Trial name
- NCT06636071
- Testing
- setrusumab
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteogenesis Imperfecta, Osteoporosis
Bisphosphonate Therapy for Osteogenesis Imperfecta
The study is designed to evaluate the efficacy and safety of "Bisphosphonate Therapy for Osteogenesis Imperfecta (OI)." We, the researchers at Indiana University School of Medicine, are characterizing the changes effected by oral…
- Conditions
- Osteogenesis Imperfecta, Osteoporosis, Paget Disease of Bone
- Trial name
- NCT00159419
- Testing
- Alendronate, Pamidronate
- Volunteers
- 18 people
- Sponsor
- Indiana University
Osteogenesis Imperfecta
Tranexamic Acid During Telescoping Nail Application In Osteogenesis Imperfecta
The aim of this study is to assess the effective of intraoperative use of tranexamic acid in reducing blood loss during telescoping nail application in cases of osteogenesis imperfecta.
- Trial name
- NCT05321199
- Testing
- Tranexamic acid
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Assiut University
Osteogenesis Imperfecta
Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
Overall Objective: To test the hypothesis that oral vitamin D supplementation at higher than currently prescribed doses has a beneficial effect on the skeleton of young patients with osteogenesis imperfecta (OI).
- Trial name
- NCT01713231
- Testing
- standard-dose vitamin D (400IU per day), high-dose vitamin D (2000 IU per day)
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Louis-Nicolas Veilleux Ph.D.
Osteogenesis Imperfecta
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical fractures at 12-months; the number of any fractures at 12-months and…
- Trial name
- NCT05972551
- Testing
- Romosozumab, Bisphosphonate
- Where
- 65 sites in United States, Australia and 16 more
- Volunteers
- 111 people
- Sponsor
- Amgen
Osteogenesis Imperfecta
Marrow Mesenchymal Cell Therapy for Osteogenesis Imperfecta: A Pilot Study
Osteogenesis imperfecta (OI) is a genetic disease for which there is currently no known cure. OI causes the osteoblasts (bone-forming cells in the body) to grow poorly, which slows the growth of children with the disease and…
- Trial name
- NCT00187018
- Testing
- Bone marrow transplant
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- St. Jude Children's Research Hospital
Osteogenesis Imperfecta
Whole Body Vibration Training in Children With Osteogenesis Imperfecta and Limited Mobility
Children with osteogenesis imperfecta (OI) have impaired bone strength, fractures, weak muscles and limited mobility. Mild to moderate forms of OI (type 1 and 4) may benefit from muscle training that leads to secondary…
- Trial name
- NCT03029312
- Testing
- Galileo M
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Birmingham Women's and Children's NHS Foundation Trust
Osteogenesis Imperfecta
Study of Osteogenesis Imperfecta Tendon
Osteogenesis imperfecta (OI) is a rare genetic disease due to a mutation in one of the genes encoding either type I collagen or a protein involved in its synthesis. This leads to bone fragility with fractures and deformities.
- Trial name
- SOIT (NCT06065111)
- Testing
- study tendon damage in osteogenesis imperfecta patients
- Where
- Belgium
- Volunteers
- 130 people
- Sponsor
- Université Catholique de Louvain
Connective Tissue Disorders, Osteogenesis Imperfecta
Evaluation and Treatment of Patients With Connective Tissue Disease
This study offers evaluation and treatment of patients with a suspected connective tissue disorder. The protocol is not designed to test new treatments; rather, patients receive standard care.
- Conditions
- Connective Tissue Disorders, Osteogenesis Imperfecta, Bone Diseases, Metabolic, Melorheostosis
- Trial name
- NCT00076830
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)